Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.

Radwan AA, Alanazi F, Al-Dhfyan A

Open source

DOI
10.1371/journal.pone.0298326
Published
2024
Container
PloS one
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0298326,
  title = {Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.},
  author = {Radwan AA and Alanazi F and Al-Dhfyan A},
  year = {2024},
  journal = {PloS one},
  doi = {10.1371/journal.pone.0298326},
  url = {https://doi.org/10.1371/journal.pone.0298326}
}

RIS

TY  - JOUR
TI  - Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
AU  - Radwan AA
AU  - Alanazi F
AU  - Al-Dhfyan A
PY  - 2024
JO  - PloS one
DO  - 10.1371/journal.pone.0298326
UR  - https://doi.org/10.1371/journal.pone.0298326
ER  - 

APA

AA, R., F, A., & A, A. (2024). Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.. PloS one. https://doi.org/10.1371/journal.pone.0298326

Source records